Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
In this study, we performed a screening of 266 gene expressions in breast carcinomas and carried out correlations with histological response to either FEC-100 (fluorouracil-epirubicin-cyclophosphamide; n = 16) or Tax-Epi (docetaxel-epirubicin; n = 12) treatment. Gene expression in biopsies obtained before and after one course of chemotherapy was analyzed. Expression of specific genes was significantly changed after one course of chemotherapy, particularly for Tax-Epi treatment. Comparison with histological response for both treatments revealed that only good responders exhibited changes in gene-expression profile. These results agree that expression of different genes changes in response to anthracycline-based neoadjuvant chemotherapy and show, for the first time, that response to docetaxel-based treatment implied also changes in gene-expression profile.
Boidot
Romain
R
Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, UMR-INSERM U-866, Dijon, France.
Vegran
Frédérique
F
Soubeyrand
Marie-Sophie
MS
Fumoleau
Pierre
P
Coudert
Bruno
B
Lizard-Nacol
Sarab
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020360:Neoadjuvant Therapy; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil